Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer




Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

• RTW committed $100M in U.S. launch funding, subject to U.S. Food and Drug Administration (FDA) approval of aglatimagene besadenovec (aglatimagene or CAN-2409) for intermediate- to high-risk localized prostate cancer                   
• Royalties based on annual net sales of aglatimagene in the U.S.
• Funds will strengthen the Company’s balance sheet for potential U.S. commercial launch of aglatimagene in intermediate- to high-risk localized prostate cancer

NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced a $100 million royalty funding agreement with funds managed by RTW Investments, LP (RTW), subject to FDA approval of aglatimagene in intermediate- to high-risk, localized prostate cancer.

“This non-dilutive strategic financing will support the U.S. launch of aglatimagene besadenovec, assuming FDA approval, and will allow us to further invest in what we believe will be a world class commercial program,” said Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO of Candel. “We remain on track to submit the BLA for aglatimagene in Q4 of this year, and we look forward to collaborating with the FDA to pursue an expeditious approval of aglatimagene. We are thrilled with our RTW partnership, as we seek to provide a new treatment option for patients in the early stages of prostate cancer who are treated with curative intent, a disease that has seen minimal innovation over the past two decades.”

“The pivotal phase 3 clinical trial demonstrated the potential of aglatimagene besadenovec in early, localized prostate cancer, and today’s commitment reflects our confidence in Candel and the strong commercial potential of this therapy,” said Roderick Wong, M.D., Managing Partner and Chief Investment Officer, RTW Investments, LP. “We are proud to partner with the Candel management team and look forward to supporting their efforts to bring this meaningful treatment to patients with localized prostate cancer.”

The commercial launch royalty financing will become available upon FDA’s approval of aglatimagene, and satisfaction of certain other customary conditions. Under the terms of the agreement, RTW will receive a tiered single digit percentage of annual net sales of aglatimagene in the U.S., subject to a cap.

About Candel Therapeutics

Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (CAN-2409 or aglatimagene) is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA). The FDA also granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC.

Linoserpaturev (CAN-3110) is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma, evaluating the effects of repeat linoserpaturev injections. Initial results were published in Nature and Science Translational Medicine and linoserpaturev received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

For more information about Candel, visit: www.candeltx.com

Forward-Looking Statements

Various statements in this release concerning the timing, size, structure and completion of the proposed public offering on the anticipated terms or at all may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. All such forward-looking statements are based on management’s current expectations of future events and are subject to a number of substantial risks and uncertainties, many of which are outside Candel’s control, that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include fluctuations in Candel’s stock price, changes in market conditions, the final terms of the public offering and satisfaction of customary closing conditions related to the public offering, as well as those risks more fully discussed in the section entitled “Risk Factors” in the prospectus supplement and registration statement referenced above, Candel’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 13, 2025 with the SEC and subsequent filings with the SEC including Candel’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. There can be no assurance that Candel will be able to complete the public offering on the anticipated terms. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Candel undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.

Investor Contact
Theodore Jenkins
Vice President, Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com

Media Contact
Ben Shannon
ICR Healthcare
CandelPR@icrhealthcare.com

Cosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to Book Value




Cosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to Book Value

CHICAGO, Feb. 19, 2026 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today highlighted the intrinsic value of its wholly owned real estate portfolio and announced that it is evaluating strategic monetization options to unlock shareholder value.

Based on independent valuation reports, recent market data, and comparable transactions, management estimates the combined fair market value of the Company’s Cana Laboratories (“Cana”) manufacturing facility and CosmoFarm logistics center at approximately $15 million. This estimate reflects the value of the land and buildings only and excludes the value of machinery and equipment housed within the facilities.

The estimated value reflects favourable macro conditions in the Greek property market. According to Bank of Greece data, residential property prices in Greece have surpassed their 2008 pre-financial crisis peak and reached record highs. Commercial real estate, including office, retail, and logistics segments, has also experienced sustained pricing and rental growth in key urban centers, particularly in Athens.

The estimated fair market value of the Company’s real estate assets exceeds the Company’s current market capitalization, which stood at approximately $13.5 million as of the close of trading on February 17, 2026.

Cana Laboratories – Neo Iraklio, Athens

The Cana property comprises a land plot of approximately 54,000 square feet and a total constructed building area of approximately 35,700 square feet. Based on the applicable building coefficient, the site allows for additional buildable capacity, subject to zoning and regulatory approvals. The property is wholly owned by the Company and is free of any mortgage or other encumbrances.

It is strategically located in Neo Iraklio, a well-established northern suburb of Athens with strong residential density and developed commercial activity. The property offers direct access to Attiki Odos, one of the primary highway arteries serving the greater Athens metropolitan area, and is within a short drive of Athens International Airport, central Athens, and surrounding business districts. It is also located just minutes from The Mall Athens, one of the largest enclosed shopping malls in Greece. Beyond its current pharmaceutical manufacturing and research and development use, the property’s location supports meaningful alternative use potential.

CosmoFarm Logistics Center – Peristeri, Athens

The CosmoFarm facility is wholly owned by the Company, consists of approximately 29,100 square feet, and is located in Peristeri, a densely populated municipality in western Athens with strong infrastructure and transport connectivity. The property currently operates as a pharmaceutical wholesale and distribution hub for Cosmos Health’s logistics subsidiary, CosmoFarm, and incorporates advanced automation and robotic systems supporting inventory management and order execution.

Strategic Optionality
At the current trading levels, the Company’s market capitalization reflects a significant discount to its reported book value (stockholders’ equity) of $23.1 million as of Q3 2025. In this context, the estimated value of the Company’s real estate portfolio represents capital that is substantial relative to its public equity value. Monetization, if pursued at or near estimated fair market value, could generate proceeds comparable to, or exceeding, the Company’s current public float.

Potential alternatives under consideration may include an outright sale, joint venture structures, sale leaseback transactions, or other strategic arrangements, subject to market conditions. Proceeds, if realized, may be used for debt reduction, reinvestment into core growth initiatives, acquisitions, or shareholder value-enhancing actions.

Greg Siokas, CEO of Cosmos Health, stated: “We believe there is a meaningful disconnect between our current valuation and the intrinsic value of our assets, with our real estate assets alone worth more than our entire market capitalization. These strategically located properties provide meaningful financial optionality. As a diversified, vertically integrated pharmaceutical company, we have a clear mission in the healthcare space. If monetizing non-core real estate assets can unlock substantial value, we will evaluate such opportunities carefully and decisively, and act accordingly.”

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.

Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com 

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/270cc392-f5ed-4611-a3af-48bc959deccd
https://www.globenewswire.com/NewsRoom/AttachmentNg/50e6cce1-f53a-40ac-8380-2ae0c0cb42a3

Aaptiv Launches New MSK App in Partnership With movr




Aaptiv Launches New MSK App in Partnership With movr

Movement Health Solution Provides Clinical-Grade Care for Musculoskeletal Pain and Recovery

CARLSBAD, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) — Aaptiv, a leading fitness and wellness platform for employers, today announced the national launch of AaptivMSK, a new musculoskeletal (MSK) health app offered in partnership with movr, delivering personalized, mobility-focused movement programs for employees.

Available through an easy-to-use app, AaptivMSK provides targeted care plans for employees experiencing, or at risk of developing, MSK issues, the number one driver of employer medical claims. Common MSK problems, such as back, neck, and shoulder pain frequently limit mobility and significantly affect employee performance and well-being.

Shift Toward Better Movement Health

“MSK pain is a common and expensive problem for employers and health plans,” said Roy Simmons, President of Aaptiv. “Movement health is the answer. It’s not just about exercising more; it’s about improving mobility, stability, strength, and balance so individuals can move and function better in daily life, with less pain and lower risk of injury.”

Simmons added, “When people can’t move comfortably, or they’re in pain, everything suffers— productivity, absenteeism, and healthcare costs. By partnering with movr, we’re bringing clinical-grade MSK care into an accessible platform that helps employees move better, feel better, and stay more active for the long term.”

A Continuum of Support: From Prevention to Recovery

With the addition of AaptivMSK, the Aaptiv platform integrates physical fitness, wellness, and targeted MSK support into a single, user-friendly experience powered by PEAR Health Labs technology. With mobility-focused programs designed for busy schedules, employees can improve MSK function in as little as five minutes a day.

Highlights include:

• Self-guided movement assessments to identify risk areas before pain escalates
• Clinically validated programming that improves range of motion and functional stability
• Personalized care plans that address specific areas like lower back, neck or shoulders, and adapt based on user feedback to ensure appropriate intensity and progression over time
• Easy integration with existing wellness programs, with measurable ROI through reduced claims and improved engagement metrics

movr: Movement Science for Everyday Fitness

“Organizations are demanding preventive MSK care that actually prevents the need for reactive and costly treatment,” said Aaron de Jong, Co-Founder of movr. “We trained and refined our MSK prescription algorithm on over 100,000 people to identify the best corrective care path to improve the issues that affect nearly half the population, so problems can be addressed earlier, before they escalate.”

De Jong added, “When mobility is integrated into everyday fitness, employers can reduce preventable MSK issues, missed workdays, and the need for more expensive care down the road.”

About Aaptiv

Aaptiv is a leading provider of digital fitness and wellness solutions for employers, health plans, and organizations nationwide. The Aaptiv platform offers guided workouts, mobility and mindfulness programs, access to the industry’s largest gym network, and clinical-grade MSK care through AaptivMSK. These solutions help organizations improve health outcomes, reduce costs, and support a healthier, more resilient workforce. For more information, visit Aaptiv.com

CONTACT: Press@aaptiv.com

Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096




Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096

• Funding to support the execution of a Phase 2 proof-of-concept trial of HER-096 in Parkinson’s disease, following completion of study preparations
  

Espoo, Finland, 19 February 2026: Herantis Pharma Plc (“Herantis”), a clinical-stage biotech company developing disease-modifying therapies to stop the progression of Parkinson’s disease, today announces that it is leading a consortium that has been selected for, pending final negotiation, an EUR 8.0 million grant from the Horizon Europe 2025 Research and Innovation program, under the ‘Boosting the translation of biotech research into innovative health therapies’ topic.

The consortium, which also includes multiple European university hospitals, will use the funding to support the execution of Herantis’ planned Phase 2, double-blind, placebo-controlled, randomized efficacy and safety study of subcutaneously administered HER-096 in patients with early-stage Parkinson’s disease. Herantis intends to initiate the study as soon as the necessary preparations, including regulatory approvals and securing additional resources, are completed.

Antti Vuolanto, CEO of Herantis Pharma, said: “We are absolutely delighted to have been selected for this non-dilutive funding from Horizon Europe. This grant will make a meaningful contribution to the funding of our Phase 2 proof-of-concept study for HER-096, the resourcing of which we are continuing to discuss with potential investors and strategic partners. Being selected from a highly competitive field of innovative European companies further validates our scientific approach and underscores the potential of HER-096 to improve outcomes for people living with Parkinson’s disease. I would like to thank the European Commission for its support and look forward to providing further updates once the agreement is signed, and the study design has been finalized.”

The ‘Boosting the translation of biotech research into innovative health therapies’ topic, which forms part of the wider Horizon Europe 2025 Health initiative, is designed to accelerate the translation of promising biotech research into clinical development and aims to deliver the following outcomes:

• Faster access to innovative therapies for healthcare providers, researchers and patients
• Increased number of clinical trials evaluating novel biotech therapeutic approaches conducted within the European Union
• Strengthened competitiveness of small and medium-size enterprises (SMEs) in the EU and Associated Countries within the health biotech sector

More information on the Horizon Europe Health initiative can be found here.

For more information, please contact:

Herantis Pharma:
Antti Vuolanto, CEO
Tel: +358407517329

Tone Kvåle, CFO
Tel: +47 915 19576
Email: ir@herantis.com

ICR Healthcare:

Sarah Elton-Farr, Stephanie Cuthbert, Phillip Marriage
Tel: +44 20 3709 5700
Email: herantispharma@icrhealthcare.com

Certified Advisor:
UB Corporate Finance Ltd
Tel.: +358 9 25 380 225
E-mail: ubcf@unitedbankers.fi

About Herantis Pharma Plc

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson’s disease. The Company’s lead product, HER-096, is a first-in-class small peptide that combines the neuroprotective mechanism of cerebral dopamine neurotrophic factor (CDNF), with the convenience of subcutaneous administration. In a Phase 1b clinical trial, HER 096 was shown to be generally safe and well tolerated in Parkinson’s disease patients. Herantis plans to advance HER-096 into a Phase 2 clinical trial in 2026 to evaluate efficacy, safety and tolerability in early-stage Parkinson’s patients.

Herantis is listed on the Nasdaq First North Growth Market Finland.

Company website: www.herantis.com

About HER-096

Herantis Pharma is developing HER-096, a first-in-class drug candidate with the potential to stop the progression of Parkinson’s disease, repair striatal damage and significantly improve both an individual’s symptoms and quality of life.

HER-096 is a small peptide molecule based on the active site of and designed to mimic the activity of cerebral dopamine neurotrophic factor (CDNF), an endogenous human protein known to promote neuronal cell survival and functional recovery.

HER-096’s multimodal mechanism of action targets key drivers of neurodegeneration in PD by modulation of the Unfolded Protein Response (UPR) pathway, reducing aggregation of the neurotoxic protein α-synuclein, and modulation of neuroinflammation. Combined with its demonstrated brain penetration, this enables HER-096 to protect dopamine neurons from further degeneration and supports their functional restoration.

Herantis has established a strong foundation of evidence in both preclinical and clinical settings. CDNF, has demonstrated robust neuroprotective and neurorestorative effects in preclinical models. In a Phase 1 clinical trial with intracranial CDNF conducted in 17 patients with moderately advanced Parkinson’s disease, encouraging signs of clinical improvements and biological responses were observed. To overcome the need for intracranial delivery required for CDNF, Herantis developed HER-096 that has shown compelling preclinical results, demonstrating the full neurorestorative potential of CDNF. Importantly, brain penetration of HER-096 has been confirmed in Parkinson’s patients at levels comparable to those associated with optimal efficacy in preclinical models, and the compound’s safety profile following subcutaneous administration has proven highly favorable. In January 2026, biomarker data from Herantis’ Phase 1b study showed clear evidence of biological response to HER-096 in people with Parkinson’s disease, with HER-096 exposure associated with changes across key disease-related pathways, aligned with the expected mechanism of action and indicating disease modifying potential.

Forward-looking statements

This release includes forward-looking statements which are not historical facts but statements regarding future expectations instead. These forward-looking statements include without limitation, those regarding Herantis’ future financial position and results of operations, the Company’s strategy, objectives, future developments in the markets in which the Company participates or is seeking to participate or anticipated regulatory changes in the markets in which the Company operates or intends to operate. In some cases, forward-looking statements can be identified by terminology such as “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “guidance,” “intend,” “may,” “plan,” “potential,” “predict,” “projected,” “should” or “will” or the negative of such terms or other comparable terminology. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance and are based on numerous assumptions. The Company’s actual results of operations, including the Company’s financial condition and liquidity and the development of the industry in which the Company operates, may differ materially from (and be more negative than) those made in, or suggested by, the forward-looking statements contained in this company release. Factors, including risks and uncertainties that could cause these differences include, but are not limited to risks associated with implementation of Herantis’ strategy, risks and uncertainties associated with the development and/or approval of Herantis’ drug candidates, ongoing and future clinical trials and expected trial results, the ability to commercialize drug candidates, technology changes and new products in Herantis’ potential market and industry, Herantis’ freedom to operate in respect of the products it develops (which freedom may be limited, e.g., by competitors’ patents), the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. In addition, even if Herantis’ historical results of operations, including the Company’s financial condition and liquidity and the development of the industry in which the Company operates, are consistent with the forward-looking statements contained in this company release, those results or developments may not be indicative of results or developments in subsequent periods.

Burcon Chiropractic Launches Meniere’s Disease Treatment Clinical Trial in Grand Rapids




Burcon Chiropractic Launches Meniere’s Disease Treatment Clinical Trial in Grand Rapids

Trial #MDTCT2026 Now Enrolling 50 Participants Diagnosed with Unilateral Meniere’s Disease

Grand Rapids, Michigan, U.S.A., Feb. 19, 2026 (GLOBE NEWSWIRE) —

Burcon Chiropractic Announces Clinical Trial for Meniere’s Disease Treatment

Burcon Chiropractic, in collaboration with the Meniere’s Research Institute, has announced the launch of a clinical trial (Trial #MDTCT2026) focused on patients diagnosed with unilateral Meniere’s disease. The study is being conducted in Grand Rapids, Michigan and will enroll up to 50 qualified participants beginning February 1, 2026.

The purpose of this clinical trial is to further investigate upper cervical care approaches in patients experiencing vertigo, hearing changes, and related symptoms associated with Meniere’s disease.

Enrollment will remain open until all 50 positions are filled.

Location

Grand Rapids, Michigan, U.S.A.

Eligibility Criteria

Participants must provide:

• Documentation confirming diagnosis of unilateral Meniere’s disease by an otolaryngologist
• Upright MRI of the head and neck, including the CranioCervical Junction (CCJ)
• Hearing test results demonstrating low-frequency hearing loss in the affected ear
• History of at least two unexplained vertigo attacks with nausea
• Completed new patient paperwork (available at www.BurconChiropractic.com)
• Completed universal Meniere’s disease questionnaire
• Availability for three office visits over a minimum of two days to two weeks in Grand Rapids, MI

Potential Benefits

Participants may:

• Contribute to ongoing Meniere’s disease research
• Experience reduction in frequency and intensity of vertigo episodes
• Receive up to $2,500 in treatment cost savings

WATCH HEALTH TALK VIDEOS

Illustrations:

1. 90% improvement with vertigo in 300 consecutive MD patients

   

2. Strong correlation between trauma and onset of Meniere’s at average of 15 years

About the Research

According to Dr. Burcon of Burcon Chiropractic, the clinical trial builds upon years of observational data examining possible correlations between prior head or neck trauma and the later onset of Meniere’s symptoms.

The study focuses on evaluating structural and neurological factors at the cranio-cervical junction using upright MRI imaging and upper cervical analysis.

Dr. Burcon has presented research related to Meniere’s disease at multiple international forums over the past 25 years, including conferences hosted by the Barany Society, House Ear Institute, Politzer Society, and International Meniere’s Disease Symposiums.

Contact Information

Meniere’s Research Institute
Burcon Chiropractic
3501 Lake Eastbrook Blvd SE
Suite 252
Grand Rapids, MI 49546

Phone: 616-575-9990
Text: 616-647-7946
Email: DrBurcon@yahoo.com

Additional Treatment Information

Individuals who do not meet all clinical trial requirements may still pursue treatment. The first three visits are available for $2,500. An intensive 12-visit care package is available for $5,000. Future visits are $150.

CONTACT: Name: Michael Burcon
Company: Meniere's Research Institute, a division of Burcon Chiropractic
Email: DrBurcon@yahoo.com
Website: https://BurconChiropractic.com
Phone: 1 616-575-9990

Family Insight Appoints Kyle Williamson as Vice President of Business Development, Accelerates Expansion and Partnerships in Value-Based Care




Family Insight Appoints Kyle Williamson as Vice President of Business Development, Accelerates Expansion and Partnerships in Value-Based Care

RICHMOND, Va., Feb. 19, 2026 (GLOBE NEWSWIRE) — Family Insight, PC, a Whitecap Care, LLC company and a leader in value-based care (VBC) and behavioral health, announces the appointment of Kyle Williamson as vice president of Business Development, strengthening the organization’s commitment to scalable partnerships with payers, healthcare systems, physician practices and high-performing value-based care models. In his new role, Williamson will lead business development strategy and support the program as it expands to multi-state partnerships and continued innovation in value-based care delivery.

“Williamson’s past partnership with Family Insight and his leadership role in developing, building and scaling Optum’s Integrated Behavioral Health Home (IBHH) program adds to our successful business model,” says Tim Kyle, CEO. “This is not simply a hire, it’s the continuation of a highly respected executive with a proven partnership that strengthens our ability to expand and deliver results for payers, providers, and the communities we serve. His transition into this leadership role formalizes a partnership that has already delivered measurable impact.”

At Optum, Williamson held a crucial management position and gained direct experience in architecting an initiative focused on the coordination of medical, behavioral, and social care for individuals with complex needs. Importantly, he was key in establishing Family Insight, PC as a vital partner for supporting this program within Virginia.

Following his tenure at Optum, Williamson evaluated numerous opportunities across the healthcare landscape but ultimately chose Family Insight because of its reputation, provider-focused culture, clear vision for the future of value-based care and focus on the overall health of the members.

“Of all of the VBC programs that I worked with, Family Insight stands out because of how intentionally they build and execute their programs,” says Williamson. “Their focus on outcomes, accountability, and true payer-provider alignment reflects exactly where healthcare needs to go. I’m excited to help grow what we’ve created together.”

Williamson brings expertise in healthcare strategy, payer-provider collaboration and value-based program development to Family Insight’s VBC team, extending Family Insight’s Complete Care Stewardship™ program with health plans, managed care organizations, accountable care organizations and hospitals across multiple states. Over the past three years, Family Insight worked closely with Williamson to refine and optimize its care delivery model based upon Optum’s requirements as well as his expectations. This collaboration helped shape the program design, operational standards and payer alignment strategies that now serve as the foundation for the company’s value-based platform.

About Family Insight, PC
Headquartered in Richmond, Virginia, Family Insight, PC specializes in Value-Based Care, integrating both medical and behavioral health to treat the whole person. We are dedicated to supporting children, adolescents, adults, and families through a comprehensive range of mental health and wellness services designed to improve long-term outcomes. https://familyinsight.net/

Media:

Laura Carabello
CPR Strategic Marketing Communications
lcarabello@cpronline.com
551.259.8248

Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026




Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026

• CDI‑988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infections
• Company to present Phase 1 data and updates from ongoing Phase 1b study conducted at Emory University School of Medicine
• No approved antiviral therapies or vaccines for norovirus infections demonstrate an immediate market need

BOTHELL, Wash., Feb. 19, 2026 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that initial progress of a norovirus challenge study with its direct-acting, oral protease inhibitor CDI-988 will be presented at the 39^th International Conference on Antiviral Research (ICAR2026), being held April 27–May 1 in Prague, Czech Republic. CDI-988 is the first oral antiviral drug candidate under development for the prevention and treatment of acute norovirus gastroenteritis.

Sam Lee, Ph.D., Cocrystal President and co-CEO, will discuss the ongoing Phase 1b challenge study evaluating CDI-988 as both a potential prophylactic and therapeutic option for norovirus infection. CDI-988 was designed and developed using the Company’s proprietary structure-based drug discovery platform technology as a pan-viral protease inhibitor, targeting 3CL viral proteases. Based on its novel mechanism of action and superior broad-spectrum antiviral activity, CDI-988 represents a potential oral treatment for both noroviruses and coronaviruses.

“ICAR is widely regarded as the premier international conference for antiviral research, and it is a privilege to be selected to present our work to this antiviral research community,” said Dr. Lee. “We are excited to further advance CDI-988 into a Phase 1b norovirus challenge study at Emory University School of Medicine. CDI‑988 is our first pan-viral protease inhibitor developed for the treatment of acute norovirus gastroenteritis and also represents a significant step toward a potential treatment for patients suffering from chronic norovirus infection.”

About ICAR2026

The International Society for Antiviral Research (ISAR) is an internationally recognized organization of scientists working across the basic, applied, translational and clinical aspects of antiviral research. The annual International Conference on Antiviral Research (ICAR), the Society’s main event, brings together virologists, chemists, clinicians, pharmacologists, biologists and regulatory representatives focused on antiviral agents and therapies. Topics include novel and broad‑spectrum antivirals, host‑targeted approaches, vaccines, pandemic preparedness and emerging or re‑emerging viral threats, with a strong emphasis on interdisciplinary collaboration among academia, industry, government and non‑profit organizations.

About Norovirus

Norovirus is a common and highly contagious virus that afflicts people of all ages and causes symptoms of acute gastroenteritis including nausea, vomiting, stomach pain and diarrhea, as well as fatigue, fever and dehydration. This infection spreads rapidly in semi-closed and crowded settings such as hospitals, nursing homes, cruise ships, schools, disaster-relief shelters and military facilities, where close contact makes outbreaks especially difficult to control. Norovirus causes an estimated 200,000 deaths worldwide each year at a societal cost of approximately $60 billion. In the U.S., norovirus is responsible for about 21 million cases of acute gastroenteritis annually, including 109,000 hospitalizations, 465,000 emergency department visits and nearly 900 deaths, with an estimated annual economic burden of $10.6 billion.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies to create viable antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential of CDI-988 as an oral treatment for both norovirus and coronavirus infections. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks and uncertainties arising from inflation, affordability, the possibility of a recession, the impact of future interest rate changes on the economy, tariffs and the resulting litigation, and geopolitical conflicts including those in Ukraine, Latin America and Middle East on our Company, our collaboration partners, and on the U.S. and global economies, including manufacturing and research delays arising from raw materials and labor shortages, supply chain disruptions and other business interruptions including any adverse impacts on our ability to obtain raw materials for and otherwise proceed with the planned norovirus study or subsequent studies as well as similar problems with our vendors and our current and any future clinical research organizations (CROs) and contract manufacturing organizations (CMOs), the progress and results of the studies including any adverse findings or delays, the ability of us and our CROs to recruit volunteers for, and to otherwise proceed with, clinical studies, our and our collaboration partners’ technology and software performing as expected, financial difficulties experienced by certain partners, the results of any current and future preclinical and clinical studies, general risks arising from clinical studies, receipt of regulatory approvals, regulatory changes and any adverse developments which may arise therefrom, potential mutations in a virus we are targeting that may result in variants that are resistant to a product candidate we develop, the potential for the development of effective treatments by competitors which could reduce or eliminate a prospective future market share commercializing any product candidates we may develop in the future, and our ability to meet our future liquidity needs. Further information on our risk factors is contained in our filings with the SEC, including the “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024 and the Prospectus dated September 25, 2025. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Contact:

Alliance Advisors IR
Jody Cain
310-691-7100
jcain@allianceadvisors.com

# # #

Philips publishes its Annual Report 2025




Philips publishes its Annual Report 2025

February 19, 2026

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2025.

Philips’ Annual Report 2025 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 8, 2026. The convocation notice and the agenda, including explanatory notes, for the AGM will be published in due course.

Philips filed the Annual Report 2025 with the Netherlands Authority for the Financial Markets (AFM) in European Single Electronic Format (ESEF) and expects to file the report on Form 20-F with the U.S. Securities and Exchange Commission later today (www.sec.gov).

The Annual Report 2025 (in ESEF and on Form 20-F) is available to shareholders and other interested parties at www.results.philips.com. A printed copy can be obtained free of charge upon written request to the following email address: annual.report@philips.com.

For further information, please contact:

Michael Fuchs
Philips Global External Relations
Tel.: +31 614 869 261
E-mail: michael.fuchs@philips.com

Dorin Danu
Philips Investor Relations
Tel.: +31 205 977 055
E-mail: dorin.danu@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements and other information
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

Reacta Healthcare Appoints Richard Nagle as Chair of Board of Directors




Reacta Healthcare Appoints Richard Nagle as Chair of Board of Directors

Pharma, Biotech and Medtech Sector Leader and Entrepreneur to Drive Further Growth and Strategic Expansion

DEESIDE, United Kingdom, Feb. 19, 2026 (GLOBE NEWSWIRE) — Reacta Healthcare Ltd, a leading developer of food allergy diagnostic products, today announces the appointment of Richard Nagle as Chair of its Board of Directors.

Richard brings more than 30 years’ experience in the pharmaceutical, biotechnology and medical technology sectors including in immunology. He has founded and led multiple companies, raised tens of millions of dollars of funding, achieved a number of successful exits and delivered operational transformations as companies grow.

Among his senior leadership positions, Richard was a Strategic Advisor and CEO at Immune Regulation (now Revolo Biotherapeutics and formerly Peptinnovate) in which roles he oversaw significant strategic advancements, clinical and product development programs and corporate development during periods of significant growth. In addition to his role as Chair of Reacta Healthcare, he is a part-time Executive Director at SASPiPhi, a company developing precision antimicrobials.

Richard’s appointment strengthens Reacta’s senior leadership as the Company continues its rapid growth driven by its leading position as the only oral food challenge product manufactured under full pharmaceutical GMP, and its innovation pipeline which will fuel future strategic expansion.

Professor Ashley Woodcock, a co-founder of Reacta Healthcare and Chair since inception, remains with the Company in a Non-Executive Director role.

Dr. Paul Abrahams, Reacta Healthcare CEO, said: “We are thrilled to have Richard join us at such a pivotal time in the Company’s growth trajectory. His specific knowledge in the immunology space and broad experience in finance, corporate strategy and product development adds huge value and strengthens our strategic leadership. The senior team and I are looking forward to working with Richard to refine and deliver on an ambitious strategy for 2026 and beyond.

“We are hugely grateful to Ashley for his entrepreneurial leadership, guidance and support of Reacta to date and look forward to his ongoing contribution to the business as a Non-Executive Director.”

Richard Nagle, Reacta Healthcare Chair, added: “This is an extremely exciting time for Reacta, and I am delighted to be joining this dynamic business. Reacta has been at the forefront of food allergy diagnostics R&D and counts many of the leading companies in the allergy therapeutic development space as its partners. Our aim now is to continue to expand our presence both in the UK and internationally, delivering solutions that improve the safety, accuracy and efficiency of food allergy testing.

“Reacta has built a world class team to execute on its future development goals, and I look forward to working with Paul and the management team in helping them to realise maximum value from its pioneering products and deep innovation pipeline.”

Reacta was recently placed 12^th in The Sunday Times Tech100 2026 fastest-growing private tech companies having expanded its multi-allergen product range to include milk and egg as well as peanut challenge meals.

About Reacta Healthcare

Reacta Healthcare is an innovative company setting a new standard in oral food challenge (OFC) products to empower the development of therapies and diagnostics to transform the lives of the millions of people living with food allergy worldwide.

The Company manufactures its products in a dedicated pharmaceutical GMP licensed-facility in the UK. The only OFC supplier working to this standard and operating worldwide.

Reacta Healthcare has been supplying clinical trials since 2017 and its OFC products have been used at over 300 sites in Europe, North America, Australia and New Zealand.

A fast-growing, profitable private company, Reacta Healthcare works with biotechnology companies, CROs and pharmaceutical majors globally and is drawing on its heritage and proven track record in food and pharmaceutical science to develop a rich pipeline of future products and solutions for the allergy market. Patents for its challenge meals have been granted in a number of countries.

For further information, please contact:

Media

Charles Consultants

Sue Charles, E: sue.charles@charles-consultants.com M: +44 (0)7968 726585
Chris Gardner, E: Chris@CGComms.onmicrosoft.com M: +44 (0)7956 031077

At the Company

Lara Marks
Marketing & Communications Officer
E: lara.marks@reactahealthcare.com T: +44 (0)3332 423 042

Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants




Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants

VICTORIA, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the pricing of its previously announced public offering (the “Offering”) of 6,428,574 common shares of the Company (the “Common Shares”) at a price to the public of US$7.00 per Common Share and pre-funded warrants to purchase up to 1,428,571 Common Shares in lieu thereof (the “Pre-Funded Warrants”) at a price of US$6.99999 per Pre-Funded Warrant, which equals the public offering price per Common Share less the C$0.00001 per share exercise price of each Pre-Funded Warrant, for gross proceeds of approximately US$55 million, before deducting the underwriting commissions and estimated expenses incurred in connection with the Offering. Each pre-funded warrant will entitle the holder thereof to acquire one common share of the Company (a “Pre-Funded Warrant Share”) at a nominal exercise price of C$0.00001 per Pre-Funded Warrant Share and will not expire until exercised in full. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,178,571 Common Shares on the same terms and conditions. All of the Common Shares and Pre-Funded Warrants in the Offering are being sold by the Company. The Offering is expected to close on February 20, 2026, subject to the satisfaction of customary closing conditions, including the listing of the Common Shares and Pre-Funded Warrant Shares to be issued under the Offering on the Toronto Stock Exchange (the “TSX”) and the Nasdaq Capital Market (the “Nasdaq”), and receipt of any required approvals of the TSX.

Cantor and LifeSci Capital are acting as joint book-running managers for the Offering. Bloom Burton and Craig-Hallum are also acting as co-managers for the Offering.

The Company intends to use the net proceeds from the Offering primarily for the continued advancement of EP-104GI for Eosinophilic Esophagitis, including the completion of ongoing preclinical studies, and Phase 2 clinical trials, preparations for a Phase 3 clinical trial including the related regulatory submissions, and manufacturing activities, and to undertake the necessary commercial/market development activities to prepare for the eventual product launch. The Company also intends to use a portion of the proceeds to accelerate and expand its plans to pursue clinical studies with EP-104GI in multiple additional gastrointestinal indications, including in esophageal strictures and fibrostenotic Crohn’s disease. A portion of the proceeds will be allocated to research and development of additional pipeline candidates, business development initiatives, and general corporate purposes, which may include but are not limited to employee salaries, working capital, leases for facilities, administrative expenses, and capital expenditures. The Company may also use a portion of the proceeds to expand its intellectual property portfolio and strengthen its corporate infrastructure to support future growth.

The Offering is being made pursuant to a U.S. registration statement on Form F-10, declared effective by the U.S. Securities and Exchange Commissions (the “SEC”) on February 7, 2024, and the Company’s existing Canadian short form base shelf prospectus, (the “Base Prospectus”) dated February 5, 2024. A preliminary prospectus supplement relating to and describing the terms of the Offering has been filed with the securities commission in all of the provinces and territories of Canada, except Quebec, and with the SEC in the United States, and a final prospectus supplement relating to and describing the terms of the Offering (the “Supplement”) will be filed with the securities commissions in all of the provinces and territories of Canada, except Quebec, and with the SEC in the United States. The Supplement and accompanying Base Prospectus contain important detailed information about the Offering.

The Supplement and accompanying Base Prospectus can be found on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Copies of the Supplement and accompanying Base Prospectus may also be obtained from Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com, from LifeSci Capital LLC at 1700 Broadway, 40^th Floor, New York, New York 10019, or by email at compliance@lifescicapital.com, from Bloom Burton Securities Inc. at ecm@bloomburton.com, or from Craig-Hallum Capital Group LLC, Attention: Equity Capital Markets, 323 North Washington Ave., Suite 300, Minneapolis, MN 55401, or by telephone at (612) 334-6300, or by email at prospectus@chlm.com. Prospective investors should read the Supplement and accompanying Base Prospectus and the other documents the Company has filed before making an investment decision.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such province, state or jurisdiction.

About Eupraxia Pharmaceuticals Inc.

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs.

Notice Regarding Forward-looking Statements and Information

This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “is expected”, “expects”, “suggests”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes”, “potential” or variations (including negative and grammatical variations) of such words and phrases, or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the Offering, whether and when the Offering may close, the satisfaction of customary closing conditions related to the Offering and the anticipated use of proceeds from the Offering; and the potential for the Company’s technology to impact the drug delivery process. Such statements and information are based on the current expectations of Eupraxia’s management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company’s ability to obtain positive results from the Company’s research and development activities, including clinical trials; and the Company’s ability to protect patents and proprietary rights. Although Eupraxia’s management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company’s limited operating history; the Company’s novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company’s current license agreement may not provide an adequate remedy for its breach by the licensor; the Company’s technology may not be successful for its intended use; the Company’s future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company’s clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its product candidates and services; the potential impact of tariffs on the cost of the Company’s active pharmaceutical ingredients and clinical supplies of EP-104IAR and EP-104GI; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company’s ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company’s operations; the Company’s restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company’s common share price; and other risks and uncertainties described in more detail in Eupraxia’s public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise.

For investor and media inquiries, please contact:
James Meikle, Eupraxia Pharmaceuticals Inc.
236.330.7084
jmeikle@eupraxiapharma.com

or

Kevin Gardner, on behalf of:
Eupraxia Pharmaceuticals Inc.
617.283.2856
kgardner@lifesciadvisors.com

SOURCE Eupraxia Pharmaceuticals Inc.